Terms: = Ovarian cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Prognosis
19 results:
1. Mutational Aberrations Detected in Mucinous Epithelial ovarian cancer of Asian Women.
Chay WY; Kwok LL; Tiong WN; Krisna SS; Lim KH; Iyer NG; Goh LK; Tan DS
Int J Gynecol Cancer; 2018 Mar; 28(3):428-436. PubMed ID: 29465505
[TBL] [Abstract] [Full Text] [Related]
2. Familial pancreatic cancer: Concept, management and issues.
Matsubayashi H; Takaori K; Morizane C; Maguchi H; Mizuma M; Takahashi H; Wada K; Hosoi H; Yachida S; Suzuki M; Usui R; Furukawa T; Furuse J; Sato T; Ueno M; Kiyozumi Y; Hijioka S; Mizuno N; Terashima T; Mizumoto M; Kodama Y; Torishima M; Kawaguchi T; Ashida R; Kitano M; Hanada K; Furukawa M; Kawabe K; Majima Y; Shimosegawa T
World J Gastroenterol; 2017 Feb; 23(6):935-948. PubMed ID: 28246467
[TBL] [Abstract] [Full Text] [Related]
3. Molecular approaches for classifying endometrial carcinoma.
Piulats JM; Guerra E; Gil-Martín M; Roman-Canal B; Gatius S; Sanz-Pamplona R; Velasco A; Vidal A; Matias-Guiu X
Gynecol Oncol; 2017 Apr; 145(1):200-207. PubMed ID: 28040204
[TBL] [Abstract] [Full Text] [Related]
4. Chromosome aberrations [dup(1q)] in endometrial cancer: Gene analysis of 54 surgical specimens in Turkey.
Sever E; Döğer E; Kumbasar S; Şık BA; Temur M; Yılmaz HT; Yılmaz Ö; Özbay PO; Yücesoy İ
Taiwan J Obstet Gynecol; 2016 Jun; 55(3):357-62. PubMed ID: 27343315
[TBL] [Abstract] [Full Text] [Related]
5. Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers.
Spaans VM; Trietsch MD; Crobach S; Stelloo E; Kremer D; Osse EM; Haar NT; van Eijk R; Muller S; van Wezel T; Trimbos JB; Bosse T; Smit VT; Fleuren GJ
PLoS One; 2014; 9(3):e93451. PubMed ID: 24671188
[TBL] [Abstract] [Full Text] [Related]
6. Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer.
Ikeda Y; Oda K; Nakagawa S; Murayama-Hosokawa S; Yamamoto S; Ishikawa S; Wang L; Takazawa Y; Maeda D; Wada-Hiraike O; Kawana K; Fukayama M; Aburatani H; Yano T; Kozuma S; Taketani Y
Int J Gynecol Cancer; 2012 Jun; 22(5):725-31. PubMed ID: 22635024
[TBL] [Abstract] [Full Text] [Related]
7. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract] [Full Text] [Related]
8. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment.
Lalwani N; Prasad SR; Vikram R; Shanbhogue AK; Huettner PC; Fasih N
Radiographics; 2011; 31(3):625-46. PubMed ID: 21571648
[TBL] [Abstract] [Full Text] [Related]
9. A precursor microRNA in a cancer cell nucleus: get me out of here!
Melo SA; Esteller M
Cell Cycle; 2011 Mar; 10(6):922-5. PubMed ID: 21346411
[TBL] [Abstract] [Full Text] [Related]
10. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract] [Full Text] [Related]
11. Role of p53 and Rb in ovarian cancer.
Corney DC; Flesken-Nikitin A; Choi J; Nikitin AY
Adv Exp Med Biol; 2008; 622():99-117. PubMed ID: 18546622
[TBL] [Abstract] [Full Text] [Related]
12. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
[TBL] [Abstract] [Full Text] [Related]
13. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis.
Dammann R; Schagdarsurengin U; Strunnikova M; Rastetter M; Seidel C; Liu L; Tommasi S; Pfeifer GP
Histol Histopathol; 2003 Apr; 18(2):665-77. PubMed ID: 12647816
[TBL] [Abstract] [Full Text] [Related]
14. [Phenotype--genotype--correlation in ovarian neoplasia].
Diebold J
Verh Dtsch Ges Pathol; 2001; 85():153-60. PubMed ID: 11894392
[TBL] [Abstract] [Full Text] [Related]
15. Role of tumour markers, cytogenetics.
Lamerz R
Ann Oncol; 1999; 10 Suppl 4():145-9. PubMed ID: 10436809
[TBL] [Abstract] [Full Text] [Related]
16. Clinicopathologic features and genetic alterations in endometrioid carcinoma of the uterus with villoglandular differentiation.
Esteller M; Garcia A; Martinez-Palones JM; Xercavins J; Reventos J
Am J Clin Pathol; 1999 Mar; 111(3):336-42. PubMed ID: 10078108
[TBL] [Abstract] [Full Text] [Related]
17. Molecular pathology of ovarian carcinomas.
Matias-Guiu X; Prat J
Virchows Arch; 1998 Aug; 433(2):103-11. PubMed ID: 9737787
[TBL] [Abstract] [Full Text] [Related]
18. The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: epidemiologic, pathologic, and molecular aspects.
Link CJ; Kohn E; Reed E
Gynecol Oncol; 1996 Mar; 60(3):347-54. PubMed ID: 8774638
[TBL] [Abstract] [Full Text] [Related]
19. The molecular basis of ovarian cancer.
Gallion HH; Pieretti M; DePriest PD; van Nagell JR
Cancer; 1995 Nov; 76(10 Suppl):1992-7. PubMed ID: 8634990
[TBL] [Abstract] [Full Text] [Related]
